These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 17696810

  • 21. Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding.
    Tu Y, Hu L, Yang C, Nemat A, Xian G, Zhang J, Zeng Q.
    Curr Atheroscler Rep; 2019 Apr 17; 21(6):22. PubMed ID: 30997584
    [Abstract] [Full Text] [Related]

  • 22. What anti-thrombotic therapy is best with primary PCI for acute ST elevation myocardial infarction: how should the HORIZONS trial change current practice?
    Brodie BR.
    Catheter Cardiovasc Interv; 2008 May 01; 71(6):816-21. PubMed ID: 18412079
    [Abstract] [Full Text] [Related]

  • 23. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI.
    Chest; 2004 Sep 01; 126(3 Suppl):576S-599S. PubMed ID: 15383485
    [Abstract] [Full Text] [Related]

  • 24. Clinical development of bivalirudin (Angiox): rationale for thrombin-specific anticoagulation in percutaneous coronary intervention and acute coronary syndromes.
    Serruys PW, Vranckx P, Allikmets K.
    Int J Clin Pract; 2006 Mar 01; 60(3):344-50. PubMed ID: 16494651
    [Abstract] [Full Text] [Related]

  • 25. Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
    Waksman R, Wolfram RM, Torguson RL, Okubagzi P, Xue Z, Suddath WO, Satler LF, Kent KM.
    J Invasive Cardiol; 2006 Aug 01; 18(8):370-5. PubMed ID: 16877786
    [Abstract] [Full Text] [Related]

  • 26. Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Lewis BE, Hursting MJ.
    Expert Rev Cardiovasc Ther; 2007 Jan 01; 5(1):57-68. PubMed ID: 17187457
    [Abstract] [Full Text] [Related]

  • 27. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
    Kwa AT, Rogers JH.
    J Interv Cardiol; 2008 Apr 01; 21(2):107-17. PubMed ID: 18248357
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
    Kao J, Lincoff AM, Topol EJ, Madrid A, J Price M, Sawhney N, Teirstein PS.
    Catheter Cardiovasc Interv; 2006 Sep 01; 68(3):352-6. PubMed ID: 16892428
    [Abstract] [Full Text] [Related]

  • 30. New anticoagulant agents: direct thrombin inhibitors.
    Nutescu EA, Shapiro NL, Chevalier A.
    Cardiol Clin; 2008 May 01; 26(2):169-87, v-vi. PubMed ID: 18406993
    [Abstract] [Full Text] [Related]

  • 31. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ, ACUITY Investigators.
    JAMA; 2007 Dec 05; 298(21):2497-506. PubMed ID: 18056903
    [Abstract] [Full Text] [Related]

  • 32. New antithrombotic agents in acute coronary syndromes.
    Moser M, Bode C.
    Curr Opin Cardiol; 2009 Jul 05; 24(4):313-7. PubMed ID: 19395952
    [Abstract] [Full Text] [Related]

  • 33. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ, REPLACE-2 Investigators.
    J Am Coll Cardiol; 2004 Sep 15; 44(6):1194-9. PubMed ID: 15364319
    [Abstract] [Full Text] [Related]

  • 34. The evolving role of direct thrombin inhibitors in acute coronary syndromes.
    Eikelboom J, White H, Yusuf S.
    J Am Coll Cardiol; 2003 Feb 19; 41(4 Suppl S):70S-78S. PubMed ID: 12644344
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
    Gurm HS, Rajagopal V, Fathi R, Vivekanathan D, Yadav JS, Bhatt DL, Ellis SG, Lincoff AM, Topol EJ.
    Am J Cardiol; 2005 Mar 15; 95(6):716-21. PubMed ID: 15757596
    [Abstract] [Full Text] [Related]

  • 36. Current role of antithrombotic agents in the treatment of acute coronary syndromes.
    Mukherjee D, Bates ER.
    Semin Thromb Hemost; 2004 Dec 15; 30(6):627-32. PubMed ID: 15630668
    [Abstract] [Full Text] [Related]

  • 37. New developments in parenteral anticoagulation for arterial and venous thromboembolism.
    van Es N, Bleker SM, Büller HR, Coppens M.
    Best Pract Res Clin Haematol; 2013 Jun 15; 26(2):203-13. PubMed ID: 23953908
    [Abstract] [Full Text] [Related]

  • 38. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
    Lincoff AM.
    Am Heart J; 2003 Oct 15; 146(4 Suppl):S23-30. PubMed ID: 14564303
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions.
    Singh S, Molnar J, Arora R.
    J Cardiovasc Pharmacol Ther; 2007 Dec 15; 12(4):283-91. PubMed ID: 18172222
    [Abstract] [Full Text] [Related]

  • 40. The role of thrombin inhibition during percutaneous coronary intervention.
    Wittkowsky AK.
    Pharmacotherapy; 2002 Jun 15; 22(6 Pt 2):97S-104S. PubMed ID: 12064571
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.